Removing One Barrier to Opioid Use Disorder Treatment: Is It Enough?

An interview with Dr Bauchner is presented. Discussed are policy reforms necessary to advance medical management of opioid use disorder in the wake of retraction by the Biden adminstration of proposed federal Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorde...

Full description

Saved in:
Bibliographic Details
Published inJAMA : the journal of the American Medical Association Vol. 325; no. 12; pp. 1147 - 1148
Main Authors Weimer, Melissa B, Wakeman, Sarah E, Saitz, Richard
Format Journal Article
LanguageEnglish
Published United States American Medical Association 23.03.2021
Subjects
Analgesics, Opioid - therapeutic use
Buprenorphine
Buprenorphine - therapeutic use
Drug addiction
Humans
Legislation, Drug
Narcotics
Opiate Substitution Treatment
Opioid Epidemic
Opioid-Related Disorders - drug therapy
Opioid-Related Disorders - epidemiology
Opioid-Related Disorders - therapy
Opioids
Practice Guidelines as Topic
United States - epidemiology
United States
Online AccessGet full text

Cover

More Information
Summary:An interview with Dr Bauchner is presented. Discussed are policy reforms necessary to advance medical management of opioid use disorder in the wake of retraction by the Biden adminstration of proposed federal Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2021.0958